Page last updated: 2024-12-05

hypericin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Hypericin is a natural compound found in the herb St. John's wort (Hypericum perforatum). It is a bright red pigment with a complex chemical structure. Hypericin is known for its potential antidepressant effects and has been studied extensively for its therapeutic properties. It exhibits photodynamic activity, meaning it can absorb light and generate reactive oxygen species that can damage cells. This property has led to research into its use as a potential treatment for cancer and other diseases. Hypericin's mechanism of action is complex and involves interactions with various cellular pathways, including neurotransmitter systems and intracellular signaling cascades. However, the exact mechanism by which hypericin exerts its effects remains under investigation. Studies have suggested that hypericin may work by inhibiting the reuptake of serotonin and other neurotransmitters, leading to increased levels of these chemicals in the brain. Additionally, it has been shown to have anti-inflammatory, antiviral, and antioxidant properties. Research into hypericin continues to explore its potential therapeutic benefits and to understand its complex biological interactions. Despite its potential, hypericin can also cause side effects, particularly when exposed to sunlight. Further research is needed to fully understand the safety and efficacy of hypericin for therapeutic purposes.'

Cross-References

ID SourceID
PubMed CID3663
CHEMBL ID286494
CHEMBL ID5082596
CHEBI ID5835
SCHEMBL ID3182
SCHEMBL ID10262695
MeSH IDM0046211

Synonyms (91)

Synonym
BIDD:PXR0084
AC-6048
ccris 8166
7v2f1075hd ,
unii-7v2f1075hd
BRD-K29673530-001-03-9
NCI60_003879
NCI60_006799
vimrxyn
HSCI1_000202
nsc-622946
nsc622946
cyclosan
nsc407313 ,
hypericum red
1,4,6,8,13-hexahydroxy-10,11-dimethylphenanthro [1,10,9,8-opqra]perylene-7,14-dione p-conformer
phenanthro[1,9,8-opqra]perylene-7,14-dione,1,3,4,6,8,13-hexahydroxy-10,11-dimethyl-, stereoisomer
nsc-407313
cyclo-werol
BIOMOLKI_000032
1,3,4,6,8,13-hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-7,14-dione
hexahydroxy(dimethyl)[?]dione
inchi=1/c30h16o8/c1-7-3-9(31)19-23-15(7)16-8(2)4-10(32)20-24(16)28-26-18(12(34)6-14(36)22(26)30(20)38)17-11(33)5-13(35)21(29(19)37)25(17)27(23)28/h3-6,31-36h,1-2h
phenanthro[1,10,9,8-opqra]perylene-7,14-dione, 1,3,4,6,8,13-hexahydroxy-10,11-dimethyl-
hypericin
548-04-9
C07606
hypericin & visible light
BIOMOLKI2_000040
NCGC00163378-01
NCGC00162454-01
1,3,4,6,8,13-hexahydroxy-10,11-dimethylphenanthro(1,10,9,8-opqra)perylene-7,14-dione
c30h16o8
4,5,7,4',5',7'-hexahydroxy-2,2'-dimethyl-mesonapthtodianthron
(component of) hypericum spp (st. john's wort)
nsc 622946
nsc 407313
einecs 208-941-0
sgx-301
sgx301
hipericin
hipericina
hyperizin
CHEBI:5835 ,
hypericine
1:6:8:10:11:13-hexahydroxy-3:4-dimethyl-meso-naphthodianthrene-7:14-dione
hypericin from hypericum perforatum, ~95% (hplc)
LMPK13040001
CHEMBL286494 ,
BMK1-D8
bdbm50060874
NCGC00163378-02
CCG-36081
FT-0627169
AKOS015895658
4,5,7,4',5',7'-hexahydroxy-2,2'-dimethylnaphthodianthrone
hypericin [usan]
hypericin [inn]
1372719-41-9
rac-(3am,10am)-1,3,4,6,8,13-hexahydroxy-10,11- dimethylphenanthro[1,10,9,8-opqra]perylene-7,14- dione
hypericin [who-dd]
SCHEMBL3182
BTXNYTINYBABQR-UHFFFAOYSA-N
CS-5687
HY-N0453
SCHEMBL10262695
Q-100618
HB3934
phenanthro(1,10,9,8-opqra)perylene-7,14-dione, 1,3,4,6,8,13-hexahydroxy-10,11-dimethyl-
mfcd00016683
DTXSID40203270
hypericin, primary pharmaceutical reference standard
SR-05000002344-2
sr-05000002344
5,7,11,18,22,24-hexahydroxy-13,16-dimethyloctacyclo[13.11.1.1(2),(1)?.0(3),?.0?,(2)?.0(1)?,(2)?.0(2)(1),(2)?.0(1)?,(2)?]octacosa-1,3,5,7,10,12,14(28),15(27),16,18,21,23,25-tridecaene-9,20-dione
AS-74733
9,11,13,16,18,20-hexahydroxy-5,24-dimethyloctacyclo[13.11.1.12,10.03,8.04,25.019,27.021,26.014,28]octacosa-1(26),2,4(25),5,8,10,12,14(28),15(27),16,18,20,23-tridecaene-7,22-dione
mycoporphyrin
hypericin from hypericum perforatum
1,3,4,6,8,13-hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-7,14-dione, 9ci
hypericin - cas 548-04-9
M01850
5,7,11,18,22,24-hexahydroxy-13,16-dimethyloctacyclo[13.11.1.12,10.03,8.04,25.019,27.021,26.014,28]octacosa-1(27),2(28),3,5,7,10,12,14,16,18,21,23,25-tridecaene-9,20-dione
hypericin (sgx301)
cyclo werro
hypericin is known as an anthroquinone derivative found in st. john's wort.
phenanthro[1,10,9,8-opqra]perylene-7,14-dione,1,3,4,6,8,13-hexahydroxy-10,11-dimethyl-, stereoisomer
A870351
who 11835
CHEMBL5082596
Z1736866019

Research Excerpts

Overview

Hypericin is a photosensitizing drug that is active against membrane-enveloped viruses and therefore constitutes a promising candidate for the treatment of SARS-CoV-2 infections. Hypericin (Hy) is a lipophilic photosensitizer extensively employed for photodynamic therapy.

ExcerptReferenceRelevance
"Hypericin (Hy) is a hydrophobic photosensitizer used in photodynamic therapy for cancer therapeutic. "( Hypericin-loaded oil-in-water nanoemulsion synthesized by ultrasonication process enhances photodynamic therapy efficiency.
Carrilho, E; Ma, HL; Perussi, JR; Varanda, LC, 2021
)
3.51
"Hypericin is a photosensitizing drug that is active against membrane-enveloped viruses and therefore constitutes a promising candidate for the treatment of SARS-CoV-2 infections. "( The Interaction of Hypericin with SARS-CoV-2 Reveals a Multimodal Antiviral Activity.
Abbruzzetti, S; Bianchini, P; Cavanna, L; Delcanale, P; Diaspro, A; Lelli, D; Mariangeli, M; Moreno, A; Mussini, A; Uriati, E; Viappiani, C, 2022
)
2.49
"Hypericin (Hy) is a potent lipid-soluble photosensitiser with promising anticancer therapeutic activities."( Hollow microneedle assisted intradermal delivery of hypericin lipid nanocapsules with light enabled photodynamic therapy against skin cancer.
Abd-El-Azim, H; Ali, A; Aly, RG; Bell, SJ; Donnelly, RF; Furlong, F; Khalafallah, N; McCarthy, HO; Mcdaid, W; Nafee, N; Rahman, T; Ramadan, A; Tekko, IA; Vora, LK, 2022
)
1.69
"Hypericin (HY) is a lipophilic photosensitizer (PS) extensively employed for photodynamic therapy (PDT), presenting high absorption in the visible region, chemical and photostability, as well as a good triplet quantum yield. "( Improved Hypericin solubility via β-cyclodextrin complexation: Photochemical and theoretical study for PDT applications.
Gusmão, LA; Machado, AEH; Perussi, JR, 2022
)
2.58
"Hypericin is a prominent secondary metabolite mainly existing in genus Hypericum. "( Hypericin: A natural anthraquinone as promising therapeutic agent.
Ding, K; He, J; Li, XX; Pan, XG; Wu, JJ; Xia, CY; Xu, JK; Zhang, J; Zhang, WK, 2023
)
3.8
"Hypericin (HYP) is a natural compound widely used as a food supplement. "( Validation of an Innovative Chromatographic Method for Hypericin Quantification in Nanostructured Lipid Carriers.
Chorilli, M; de Araújo, PR; Luiz, MT; Sato, MR, 2023
)
2.6
"Hypericin (HY) is an excellent compound that has been investigated in antiviral, antineoplastic, and antidepressant."( Protective effects of hypericin against infectious bronchitis virus induced apoptosis and reactive oxygen species in chicken embryo kidney cells.
Abbas, G; Chen, H; Diao, L; Feng, R; Huang, X; Li, G; Muhammad, I; Ren, Y; Wang, X; Zhang, R; Zhang, Y, 2019
)
1.55
"Hypericin (Hyp) is a naturally occurring compound used as photosensitizer in photodynamic therapy and diagnosis. "( Importance of Hypericin-Bcl2 interactions for biological effects at subcellular levels.
Huntosova, V; Kozar, T; Stroffekova, K; Tomkova, S, 2019
)
2.32
"Hypericin (HYP) is a naturally-occurring pigment obtained from some plants of the genus Hypericum. "( A Review of Analytical Methods for the Determination of Hypericin in Foods, Herbal, Biological and Pharmaceutical Matrices.
Chorilli, M; de Araújo, PR; Fonseca-Santos, B; Kogawa, AC; Salgado, HRN, 2020
)
2.25
"Hypericin (HYP) is an active compound of "( Elucidation the binding interaction of hypericin-loaded P84 copolymeric micelles by using 1D and 2D NMR techniques.
Caetano, W; de Oliveira, ACV; Gonçalves, RS; Hioka, N, 2022
)
2.43
"Hypericin is a polycyclic aromatic naphthodianthrone that occurs naturally. "( Hypericin-mediated photodynamic therapy for the treatment of cancer: a review.
Cruz, LJ; Dong, X; Fu, J; Gu, Z; Hao, Y; He, Y; Ni, J; Qu, C; Yin, X; You, L; Yu, Z; Zeng, Y; Zhang, Z, 2021
)
3.51
"Hypericin is a powerful photosensitizer with pronounced tumor-localizing properties."( Hypericin-mediated photodynamic therapy inhibits growth of colorectal cancer cells via inducing S phase cell cycle arrest and apoptosis.
Chen, L; Hu, J; Song, J; Tang, Z; Wei, S; Zhou, R, 2021
)
2.79
"Hypericin is an endoplasmic reticulum (ER)-located photosensitizer, which causes oxidative damage to ER during photodynamic therapy (PDT). "( Endoplasmic reticulum-targeting photosensitizer Hypericin confers chemo-sensitization towards oxaliplatin through inducing pro-death autophagy.
Du, W; Liang, X; Lin, S; Liu, J; Qi, Y; Qiu, C; Shi, H; Shi, W; Yang, L, 2017
)
2.15
"Hypericin (Hyp) is a natural photoactive pigment utilized in the treatment of different types of cancer and antimicrobial inactivation using photodynamic therapy (PDT). "( Preparation and characterization of bioadhesive system containing hypericin for local photodynamic therapy.
Baesso, ML; Borghi-Pangoni, FB; Bruschi, ML; Caetano, W; de Castro, LV; de Souza Ferreira, SB; Diniz, A; Junqueira, MV; Rabello, BR; Silva, LL, 2017
)
2.13
"Hypericin (Hyp) is a hydrophobic pigment found in plants of the genus Hypericum which exhibits low levels of solubility in water. "( Excitation of triplet states of hypericin in water mediated by hydrotropic cromolyn sodium salt.
Antalík, M; Jancura, D; Keša, P; Kudláčová, J; Valušová, E, 2018
)
2.21
"Hypericin (Hy) is a promising PS; however, its clinical application is significantly limited by its poor hydrophilicity."( Facile fabrication of hypericin-entrapped glyconanoparticles for targeted photodynamic therapy.
Pei, Y; Pei, Z; Shang, K; Shao, C; Xu, H; Zhang, Y, 2018
)
1.52
"Hypericin (HY) is a naturally-occurring photosensitizer synthesized by plants of the genus Hypericum."( Breast cancer resistance protein is the enemy of hypericin accumulation and toxicity of hypericin-mediated photodynamic therapy.
Fedoročko, P; Jendželovská, Z; Jendželovský, R; Kuchárová, B, 2019
)
1.49
"Hypericin (HY) is a new-type of photosensitizer in the context of photodynamic therapy (PDT) due to its excellent photosensitizing properties and anti-tumor activities."( Hypericin-photodynamic therapy inhibits the growth of adult T-cell leukemia cells through induction of apoptosis and suppression of viral transcription.
Cheng, W; Shao, L; Wang, Y; Wang, Z; Xu, L; Yi, K; Zhang, X; Zhang, Y; Zhao, T, 2019
)
2.68
"Hypericin is a molecule of high pharmaceutical importance that is synthesized and stored in dark glands (DGs) of St. "( Discovery of key regulators of dark gland development and hypericin biosynthesis in St. John's Wort (Hypericum perforatum).
Altschmied, L; Bäumlein, H; Borisjuk, L; Franke, K; Gündel, A; Koch, M; Rizzo, P; Rutten, T; Scharfenberg, S; Sharbel, TF; Stark, P; Wessjohann, L, 2019
)
2.2
"Hypericin (Hyp) is a natural compound with interesting photophysical and pharmacological properties, which has been used in photodynamic therapy and photodynamic inactivation of microorganisms. "( From Protohypericin to Hypericin: Photoconversion Analysis Using a Time-Resolved Thermal Lens Technique.
Astrath, NGC; Caetano, W; Camargo, VG; Gonçalves, RS; Herculano, LS; Hioka, N; Lukasievicz, GVB; Malacarne, LC; Pereira, PCS; Zanuto, VS, 2019
)
2.36
"Hypericin is a photosensitizer with promising applications in photodynamic therapy (PDT) for cancer and infectious diseases treatments. "( Structural and photophysical properties of peptide micro/nanotubes functionalized with hypericin.
Alves, WA; Ávilla, Éde S; da Silva, ER; de Andrade, GP; Fileti, EE; Jaques, YM; Krambrock, K; Pinheiro, MV; Ribeiro, AO; Souza, MI, 2013
)
2.06
"Hypericin (Hyp) is a promising photosensitizer for photodiagnostic and photodynamic therapy of cancer. "( Solubilization of poorly soluble photosensitizer hypericin by polymeric micelles and polyethylene glycol.
Búzová, D; Jancura, D; Kasák, P; Miškovský, P, 2013
)
2.09
"Hypericin (HYP) is a natural photosensitizer considered for the new generation of photodynamic therapy (PDT) drugs. "( Photodynamic effect of hypericin on the microorganisms and primary human fibroblasts.
Borghei, YS; Djavid, GE; Kashef, N, 2013
)
2.14
"Hypericin (HY) is a naturally-occurring, potent photosensitizer. "( Antibiotic-free nanotherapeutics: hypericin nanoparticles thereof for improved in vitro and in vivo antimicrobial photodynamic therapy and wound healing.
Asem, H; El-Gowelli, H; Kandil, S; Nafee, N; Youssef, A, 2013
)
2.11
"Hypericin is a promising phototoxic drug which was investigated for its effects on head neck squamous cell carcinoma cells in vitro."( Photosensitizing effects of hypericin on head neck squamous cell carcinoma in vitro.
Bootz, F; Busse, AC; Gerstner, AO; Laffers, W; Mahrt, J; Nguyen, P; Wessels, JT, 2015
)
1.43
"Hypericin (HY) is a promising photosensitizer (PS) for use in photodynamic therapy (PDT). "( Hypericin damages the ectatic capillaries in a Roman cockscomb model and inhibits the growth of human endothelial cells more potently than hematoporphyrin does through induction of apoptosis.
Fu, RQ; Guan, HY; Li, CW; Li, YY; Li, ZH; Lu, LC; Meng, DS; Yang, X; Yu, CP; Zhang, Q,
)
3.02
"Hypericin is a natural photosensitizer used in photodynamic therapy (PDT), which has shown in vitro antifungal effect against Candida spp. "( In vitro fungicidal photodynamic effect of hypericin on Trichophyton spp.
Alejandre, C; Gilaberte, Y; Pardo, J; Paz-Cristobal, MP; Revillo, MJ; Rezusta, A, 2014
)
2.11
"Hypericin (HY) is a photoactive aromatic dianthraquinone that is considered a potent photodynamic agent. "( Photodynamic efficiency of hypericin compared with chlorin and hematoporphyrin derivatives in HEp-2 and Vero epithelial cell lines.
Andrade, GP; Bernal, C; Perussi, JR; Ribeiro, AO, 2015
)
2.16
"Hypericin is a natural polycyclic quinone found in Hypericum perforatum. "( Permeation Characteristics of Hypericin across Caco-2 Monolayers in the Absence or Presence of Quercitrin - A Mass Balance Study.
Abdel-Aziz, H; Brügger, D; Butterweck, V; Verjee, S, 2015
)
2.15
"Hypericin is an important component of the Saint John's wort (Hypericum perforatum). "( [Effect of Hypericin on the Function of the Neuroretina: An Electroretinographic Study].
Abumuaileq, R; Albanna, W; Alnawaiseh, M; Böhm, MR; Eter, N; Schneider, T, 2015
)
2.25
"Hypericin is a photosensitizer compound used in the photodynamic therapy (PDT). "( Purification of Glutathione S-Transferase pi from Erythrocytes and Evaluation of the Inhibitory Effect of Hypericin.
Dalmizrak, O; Kulaksiz Erkmen, G; Ogus, IH; Ozer, N; Turk, S, 2015
)
2.07
"Hypericin is a well-studied photosensitizer."( Enhancement of oxaliplatin sensitivity in human colorectal cancer by hypericin mediated photodynamic therapy via ROS-related mechanism.
Du, W; Gao, Y; Lei, K; Liang, X; Lin, S; Liu, J; Shi, H; Yang, L; Yin, P, 2016
)
1.39
"Hypericin (HY) is an interesting photosensitizer with dark activity and photodynamic therapy (PDT) effects via p53-independent pathway. "( Potentiation of the photodynamic action of hypericin.
Heng, PW; Olivo, M; Saw, CL, 2008
)
2.05
"Hypericin is a photo-active dye originating from the St. "( Topical treatment of disseminated superficial actinic porokeratosis with hypericin-photodynamic therapy: a case report.
Boiy, A; de Witte, PA; Roelandts, R, 2010
)
2.03
"Hypericin is a known photodynamic agent that has been demonstrated to induce apoptosis in normal and malignant B and T lymphocytes, and has potential to treat benign and malignant disorders of the skin, including psoriasis and cutaneous T-cell lymphoma."( A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis.
Cabana, B; Duvic, M; Rook, AH; Tobia, A; Vonderheid, EC; Wood, GS, 2010
)
2.03
"Hypericin is a bright red fluorescent compound that can be used in urological medicine as a photodiagnostic to detect non-muscle-invasive bladder cancer lesions. "( Human serum albumin as key mediator of the differential accumulation of hypericin in normal urothelial cell spheroids versus urothelial cell carcinoma spheroids.
de Witte, PA; Lerut, E; Roelants, M; Van Cleynenbreugel, B; Van Poppel, H, 2011
)
2.04
"Hypericin is a photosensitizer expressing high affinity for cancerous cells in vivo. "( Hypericin incorporation and localization in fixed HeLa cells for various conditions of fixation and incubation.
Bonneau, S; Bourg-Heckly, G; Vever-Bizet, C; Vuong, TT, 2011
)
3.25
"Hypericin (Hyp) is a natural photosensitizing pigment with a possible application in the photodynamic therapy of cancer. "( On the diffusion of hypericin in dimethylsulfoxide/water mixtures-the effect of aggregation.
Bánó, G; Bánó, M; Jancura, D; Marek, J; Miškovský, P; Staničová, J; Strejčková, A; Uličný, J, 2011
)
2.14
"Hypericin is a potent inhibitor of glioma growth in vitro. "( A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas.
Appley, AJ; Cabana, BE; Chen, TC; Couldwell, WT; Forsyth, PA; Hinton, DR; Spence, AM; Stillerman, CB; Surnock, AA; Tobia, AJ, 2011
)
2.06
"Hypericin is a natural photosensitizer considered for the new generation of photodynamic therapy (PDT) drugs. "( In vitro fungicidal photodynamic effect of hypericin on Candida species.
Agut, M; Alemany-Ribes, M; Aspiroz, C; Gilaberte, Y; López-Chicón, P; Nonell, S; Paz-Cristobal, MP; Revillo, MJ; Rezusta, A; Royo-Díez, D; Semino, C,
)
1.84
"Hypericin (Hyp) is a hydrophobic natural photosensitizer that is considered to be a promising molecule for photodynamic treatment of tumor cells and photo-diagnosis of early epithelial cancers. "( Cell death response of U87 glioma cells on hypericin photoactivation is mediated by dynamics of hypericin subcellular distribution and its aggregation in cellular organelles.
Dzurova, L; Huntosova, V; Jakusova, V; Miskovsky, P; Nadova, Z; Sureau, F, 2012
)
2.08
"Hypericin (HYP) is a naturally occurring photosensitizer. "( In vitro comparison of hypericin and 5-aminolevulinic acid-derived protoporphyrin IX for photodynamic inactivation of medulloblastoma cells.
Dietz, K; Noell, S; Ritz, R; Roser, F; Scheidle, C; Schenk, M; Strauss, WS, 2012
)
2.13
"Hypericin is a promising photosensitizer for photodynamic therapy (PDT) characterized by a high yield of singlet oxygen. "( Photobleaching of hypericin bound to human serum albumin, cultured adenocarcinoma cells and nude mice skin.
Iani, V; Ma, LW; Moan, J; Uzdensky, AB, 2002
)
2.09
"Hypericin is a photosensitizing plant pigment from Hypericum perforatum with multiple modes of light-induced biological activities due to production of singlet oxygen and/or excited-state proton transfer with consequent pH drop in the hypericin environment. "( Modulation of the phototoxic effect of hypericin in human leukemia CEM cell line by N-ethylmaleimide, amiloride and omeprazole.
Mirossay, A; Mirossay, L; Mojzis, J; Papp, P; Sarisský, M, 2002
)
2.03
"Hypericin is a very promising new photosensitizer for innovative photodynamic therapy of esophageal cancer. "( Hypericin activated by an incoherent light source has photodynamic effects on esophageal cancer cells.
Höpfner, M; Kashtan, H; Lenz, M; Maaser, K; Riecken, EO; Scherübl, H; Sutter, AP; Theiss, A; von Lampe, B; Zeitz, M, 2003
)
3.2
"Hypericin appears to be an effective photosensitizer for the treatment of NPC."( Biodistribution and photodynamic therapy with hypericin in a human NPC murine tumor model.
Bay, BH; Du, HY; Olivo, M, 2003
)
1.3
"Hypericin is a photosensitizer, which is known to generate reactive oxygen species upon activation with light."( Photoactivation of hypericin down-regulates glutathione S-transferase activity in nasopharyngeal cancer cells.
Bay, BH; Du, HY; Olivo, M; Tan, BK, 2004
)
1.37
"Hypericin (HYP) is a major constituent of the herbal antidepressant St. "( A novel antioxidant role for ligandin behavior of glutathione S-transferases: attenuation of the photodynamic effects of hypericin.
Atkins, WM; Lu, WD, 2004
)
1.97
"Hypericin is a photosensitizing pigment found in St. "( Hypericin and photodynamic treatment do not interfere with transport of vitamin C during respiratory burst.
Goldenberg, H; Laggner, H; Schmid, S, 2004
)
3.21
"Hypericin is a naturally occurring substance found in the common St. "( Hypericin--the facts about a controversial agent.
Alth, G; Burner, U; Grünberger, W; Kubin, A; Wierrani, F, 2005
)
3.21
"Hypericin is a potent agent in the photodynamic therapy of cancers. "( Elucidation of the tumoritropic principle of hypericin.
Agostinis, P; de Witte, PA; Roskams, T; Van de Putte, M; Vandenheede, JR, 2005
)
2.03
"Hypericin is a potent agent in the photodynamic therapy of cancers and accumulates to a large extent in tumor tissue. "( The impact of aggregation on the biodistribution of hypericin.
Bormans, G; De Witte, PA; Roskams, T; Van De Putte, M; Verbruggen, A, 2006
)
2.03
"Hypericin is a naturally occurring metabolite extracted from Hypericum plants and is regarded as a promising photosensitizing agent for applications in the frame of photodynamic treatment (PDT). "( Characterization of apoptosis induced by photodynamic treatment with hypericin in A431 human epidermoid carcinoma cells.
Berlanda, J; Kiesslich, T; Krammer, B; Oberdanner, CB; Obermair, FJ; Plaetzer, K, 2006
)
2.01
"Hypericin is a naturally occurring secondary metabolite in plants of the Hypericum genus, with Hypericum perforatum (St."( Cellular mechanisms and prospective applications of hypericin in photodynamic therapy.
Kiesslich, T; Krammer, B; Plaetzer, K, 2006
)
1.31
"Hypericin (HY) is a promising photosensitizer in photodynamic therapy (PDT). "( Spectroscopic characterization and photobleaching kinetics of hypericin-N-methyl pyrrolidone formulations.
Heng, PW; Olivo, M; Saw, CL; Soo, KC, 2006
)
2.02
"Hypericin is an active ingredient in the medical herb St."( Hypericin inhibits pathological retinal neovascularization in a mouse model of oxygen-induced retinopathy.
Higuchi, A; Jo, N; Matsumura, M; Yamada, E; Yamada, H, 2008
)
2.51
"Hypericin is a polycyclic, aromatic, naphthodianthrone which has been shown to possess in vivo and in vitro antiretroviral activity. "( Photodynamic inactivation of radiation leukemia virus produced from hypericin-treated cells.
Degar, S; Lavie, G; Meruelo, D, 1993
)
1.96
"Hypericin is a potent virucidal agent with activity against a broad range of enveloped viruses and retroviruses. "( Hypericin as an inactivator of infectious viruses in blood components.
Lavie, D; Lavie, G; Levin, B; Liebes, L; Mazur, Y; Meruelo, D; Pascual, D; Prince, AM, 1995
)
3.18
"Hypericin is a naturally occurring photosensitizer that displays potent antiviral activity in the presence of light. "( Chemiluminescent activation of the antiviral activity of hypericin: a molecular flashlight.
Carpenter, S; Fehr, MJ; Kraus, GA; Petrich, JW, 1994
)
1.98
"Hypericin is a naturally occurring photosensitizer, whose presence in plants has been responsible for cutaneous phototoxicity in grazing animals. "( Hypericin-induced phototoxicity in cultured fibroblasts and swine erythrocytes.
Kegode, R; Osweller, GD; Wolford, ST; Yu, H; Zhao, W, 1996
)
3.18
"Hypericin is a polycyclic quinone, which has been shown to possess in vivo and in vitro antiretroviral and photosensitizing activity; moreover, it is used in depressive disorders."( Hypericin in phototherapy.
Alth, G; Ebermann, R; Jindra, RH; Koderhold, G; Koren, H; Kreitner, M; Kubin, A; Schenk, GM, 1996
)
2.46
"Hypericin is a photodynamic compound activated by either visible (400-700 nm) or UVA (320-400 nm) light, and has been shown to inhibit the growth of a variety of neoplastic cell types. "( Photoactivated hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal, transformed, and malignant T lymphocytes: implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders.
Fox, FE; Niu, Z; Rook, AH; Tobia, A, 1998
)
2.1
"Hypericin is a natural photo-active pigment produced by plants of the genus Hypericum. "( Confluence dependent resistance to photo-activated hypericin in HeLa cells.
Agostinis, P; De Witte, PA; Delaey, EM; Vandenbogaerde, AL, 1999
)
2
"Hypericin (HY) is a powerful photo-inducer of apoptosis in Jurkat cells as measured by caspase-3 activation, cell shrinkage, phosphatidylserine (PS) exposure and the appearance of hypoploid DNA. "( Over-expression of Bcl-2 does not protect cells from hypericin photo-induced mitochondrial membrane depolarization, but delays subsequent events in the apoptotic pathway.
Chaloupka, R; Israël, N; Petit, PX; Sureau, F, 1999
)
2
"Hypericin is a unique photosensitizing plant pigment and has been separately reported to induce differentiation and apoptosis in neoplastic cells. "( Hypericin induces both differentiation and apoptosis in human promyelocytic leukemia HL-60 cells.
Chang, SG; Jung, JC; Kim, JI; Lee, KT; Miyamoto, K; Park, HJ; Park, JH; Rho, YS, 1999
)
3.19
"Hypericin is a natural derivative of the common St. "( Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection.
Cabana, BE; Feinman, L; Jacobson, JM; Koslowski, V; Lee, D; Liebes, L; Ostrow, N; Prince, AM; Spritzler, J; Tobia, A, 2001
)
2.01
"Hypericin (HYP) is a photosensitizing pigment from Hypericum perforatum that displays cytotoxic effects in neoplastic cell lines. "( Hypericin photo-induced apoptosis involves the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and activation of caspase-8.
Schempp, CM; Simon, JC; Simon-Haarhaus, B; Termeer, CC, 2001
)
3.2
"Hypericin is a natural photosensitizer produced in plants of the genus Hypericum. "( Synergistic effect of photodynamic therapy with hypericin in combination with hyperthermia on loss of clonogenicity of RIF-1 cells.
Agostinis, P; Chen, B; De Witte, PA; Xu, Y, 2001
)
2.01
"Hypericin is a protein tyrosine kinase inhibitor that has been exploited in models for anti-tumor and anti-viral activity."( Inhibition of c-erbB-2 expression an activity in human ovarian carcinoma cells by hypericin.
Gee, SW; Hwang, MS; Joo, JH; Kang, HI; Kim, OH; Kim, S; Lee, KK; Yum, YN,
)
1.08
"Hypericin is a naturally occurring photosensitizer with promising properties for the PDT of cancer."( Phosphorylation of Bcl-2 in G2/M phase-arrested cells following photodynamic therapy with hypericin involves a CDK1-mediated signal and delays the onset of apoptosis.
Agostinis, P; Assefa, Z; De Witte, PA; Merlevede, W; Piette, J; Vandenheede, JR; Vantieghem, A; Xu, Y, 2002
)
1.26
"Hypericin is a polycyclic anthrone first isolated from the plant St. "( Virucidal activity of hypericin against enveloped and non-enveloped DNA and RNA viruses.
Colacino, JM; Larsen, SH; Spitzer, W; Tang, J, 1990
)
2.04

Effects

Hypericin has an extremely high affinity for the cell membrane and is found to a smaller extent in the nucleus. We explored small-molecular tumor necrosis therapy (SMTNT) for inhibiting tumor growth in rodents.

Hypericin has been reported as a potent photosensitizing agent exhibiting antiviral, antibacterial, antineoplastic activities. It has found applications in photodynamic diagnostics solely due to its high specificity for tumour cells and tissues.

ExcerptReferenceRelevance
"Hypericin has a remarkable killing effect on T. "( [In vitro Effect of Hypericin against Toxoplasma gondii Tachyzoites].
Chen, XZ; Cui, J; Ding, YH; Fang, Q; Hu, SF; Ji, YS; Li, JY; Meng, LW; Qiao, JC; Song, D; Su, PP; Sun, XM; Wang, Q; Wu, Q; Xue, HB; Yang, XD, 2016
)
2.2
"Hypericin has an excellent necrosis-specific targeting capacity; thus, we explored small-molecular tumor necrosis therapy (SMTNT) for inhibiting tumor growth in rodent tumor models. "( Biodistribution and anti-tumor efficacy of intratumorally injected necrosis-avid theranostic agent radioiodinated hypericin in rodent tumor models.
Feng, Y; Gao, M; Huang, D; Jiang, C; Jiang, X; Jing, S; Li, Y; Liu, W; Ni, Y; Peng, F; Wang, X; Zhang, D; Zhang, J, 2015
)
2.07
"Hypericin has an extremely high affinity for the cell membrane and is found to a smaller extent in the nucleus."( Subcellular distributions and excited-state processes of hypericin in neurons.
Doyle, RT; English, DS; Haydon, PG; Petrich, JW, 1999
)
1.27
"Hypericin has shown anticancer activity against the expansion of several cell types including breast cancer, cervical cancer, colorectal cancer, colon cancer, hepatocellular carcinoma, stomach carcinoma, leukemia, lung cancer, melanoma, and glioblastoma cancer."( Hypericin and its anticancer effects: From mechanism of action to potential therapeutic application.
Bishayee, A; Choudhary, N; Collignon, TE; Tewari, D, 2022
)
2.89
"Hypericin-PDT has reduced efficacy in CRC spheroids as compared to 2D cultures, which may be attributable through upregulation in ABCG2. "( Inhibiting ABCG2 could potentially enhance the efficacy of hypericin-mediated photodynamic therapy in spheroidal cell models of colorectal cancer.
Andrew, H; Armstrong, G; Hughes, TA; Jayne, DG; Kapur, N; Khot, MI; Maisey, T; Perry, SL, 2018
)
2.17
"Hypericin has been reported to be a good antiviral agent for inhibiting HCV replication, however, little is known about its mechanisms of action. "( Hypericin inhibits hepatitis C virus replication via deacetylation and down-regulation of heme oxygenase-1.
Hsiao, YM; Ko, JL; Shih, CM; Wu, CH; Wu, WJ, 2018
)
3.37
"Hypericin has a remarkable killing effect on T. "( [In vitro Effect of Hypericin against Toxoplasma gondii Tachyzoites].
Chen, XZ; Cui, J; Ding, YH; Fang, Q; Hu, SF; Ji, YS; Li, JY; Meng, LW; Qiao, JC; Song, D; Su, PP; Sun, XM; Wang, Q; Wu, Q; Xue, HB; Yang, XD, 2016
)
2.2
"Hypericin has been widely studied as a potent photosensitizer for photodynamic therapy in both preclinical and clinical settings. "( Necrosis avidity: a newly discovered feature of hypericin and its preclinical applications in necrosis imaging.
Chen, F; Jiang, B; Ni, Y; Wang, J, 2013
)
2.09
"Hypericin (HYP) has been found avid to necrosis in small animal studies. "( Radiopharmaceutical study on Iodine-131-labelled hypericin in a canine model of hepatic RFA-induced coagulative necrosis.
Ni, Y; Qi, X; Shao, H; Sun, Z; Xu, K; Zhang, J, 2015
)
2.11
"Hypericin (Hy) has shown great promise as a necrosis-avid agent in cancer imaging and therapy. "( Evaluation of hypericin: effect of aggregation on targeting biodistribution.
Gao, M; Huang, D; Ji, Y; Jiang, C; Li, Y; Liu, W; Liu, X; Ni, Y; Sun, Z; Yao, N; Yin, Z; Zhang, J, 2015
)
2.22
"Hypericin has an excellent necrosis-specific targeting capacity; thus, we explored small-molecular tumor necrosis therapy (SMTNT) for inhibiting tumor growth in rodent tumor models. "( Biodistribution and anti-tumor efficacy of intratumorally injected necrosis-avid theranostic agent radioiodinated hypericin in rodent tumor models.
Feng, Y; Gao, M; Huang, D; Jiang, C; Jiang, X; Jing, S; Li, Y; Liu, W; Ni, Y; Peng, F; Wang, X; Zhang, D; Zhang, J, 2015
)
2.07
"Hypericin has been reported as a potent photosensitizing agent exhibiting antiviral, antibacterial, antineoplastic activities. "( Fluorescence study on the interaction between hypericin and lens protein "alpha-crystallin".
Youssef, T,
)
1.83
"Hypericin has excellent photosensitizing properties and displays favorable tumouritropic characteristics, but at the same time exhibits minimal dark toxicity. "( In vitro study of the photocytotoxicity of bathochromically-shifted hypericin derivatives.
Agostinis, P; de Witte, PA; Falk, H; Lackner, B; Roelants, M; Van Poppel, H; Waser, M, 2009
)
2.03
"Hypericin has been attracting a growing attention of the pharmaceutical industry because of its potential application in various therapies, including the treatment of depression."( Crystal structure of Hyp-1, a St. John's wort protein implicated in the biosynthesis of hypericin.
Fernandes, H; Jaskolski, M; Michalska, K; Sikorski, M, 2010
)
1.3
"Hypericin (HY) has found applications in photodynamic diagnostics solely due to its high specificity for tumour cells and tissues."( Lower sensitivity of FHC fetal colon epithelial cells to photodynamic therapy compared to HT-29 colon adenocarcinoma cells despite higher intracellular accumulation of hypericin.
Fedoročko, P; Hofmanová, J; Hýžďalová, M; Jendželovský, R; Kočí, L; Kovaľ, J; Kozubík, A; Mikeš, J; Vaculová, A, 2011
)
1.29
"Hypericin has attracted a growing attention of the pharmaceutical industry because of its potential application to various therapies, including the treatment of depression and remarkable antiviral and photodynamic activities, hyp-1 gene encodes for phenolic coupling protein which catalyzes in vitro direct and specific conversion of emodin to hypericin which, however, has not formed common opinion so far."( [Rapid cloning and functional characterization of hypericin synthase gene].
An, JM; Kong, JQ; Shi, YW; Wang, W; Yang, Y; Zheng, HN; Zhi, XH, 2012
)
1.35
"Hypericin has potential as a therapeutic drug for proliferative vitreoretinopathy(PVR), the inhibitory effect on PVR might be caused by blocking the PKC activity and inhibiting Ca2+ influx pathway."( Effect of hypericin on confocal imaging of Ca2+ signaling in cultured human retinal pigment epithelium.
Gao, Q; Hui, Y; Wang, L; Wang, Y, 2001
)
1.43
"Hypericin (Hyp) has been proposed as a fluorochrome for fluorescence diagnostics and as a photosensitizer for photodynamic therapy of cancer. "( Photodynamic effect of hypericin and a water-soluble derivative on isolated crayfish neuron and surrounding glial cells.
Bragin, DE; Kolosov, MS; Kubin, A; Loew, HG; Moan, J; Uzdensky, AB, 2003
)
2.07
"Hypericin (HY) has been found to be superior to 5-aminolevulinic acid (5-ALA) and its ester derivative hexaminolevulinate (HA) as a fluorescence diagnostic agent, hence its development for delivery in vitro and in vivo, is the subject of this review."( Delivery of hypericin for photodynamic applications.
Heng, PW; Olivo, M; Saw, CL; Soo, KC, 2006
)
1.43
"As hypericin has been found to bind to LDL one may assume that it can act as antioxidant of LDL lipid oxidation, a property which is of prophylactic/therapeutic interest regarding atherogenesis as LDL oxidation may play a pivotal role in the onset of atherosclerosis."( The main components of St John's Wort inhibit low-density lipoprotein atherogenic modification: a beneficial "side effect" of an OTC antidepressant drug?
Exner, M; Gmeiner, BM; Hermann, M; Kapiotis, S; Laggner, H; Mühl, A; Schreier, S, 2007
)
0.85
"Hypericin has absorption maxima at 545 and 590 nm with a fluorescence emission peak at 640 nm in ethanol."( Hypericin uptake in rabbits and nude mice transplanted with human squamous cell carcinomas: study of a new sensitizer for laser phototherapy.
Castro, DJ; Chung, PS; Foote, C; Mathey, A; Paiva, MB; Rhee, CK; Saxton, RE; Soudant, J, 1994
)
2.45
"Hypericin has an extremely high affinity for the cell membrane and is found to a smaller extent in the nucleus."( Subcellular distributions and excited-state processes of hypericin in neurons.
Doyle, RT; English, DS; Haydon, PG; Petrich, JW, 1999
)
1.27
"Oral hypericin has entered clinical trials in adults with recurrent malignant glioma."( Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in nonhuman primates.
Adamson, PC; Fox, E; McCully, CL; Murphy, RF, 2001
)
1.01
"Hypericin has potent activity against HIV and other viruses, is compatible with anticoagulants used to store blood, and does not affect blood chemistry when stored for 21 days. "( Hypericin: an answer for safer blood?
Kuhn, D, 1995
)
3.18
"Hypericin (HYP) has been reported to have photodependent cytotoxic activity in a variety of cancer cell lines. "( Tumor-specific and photodependent cytotoxicity of hypericin in the human LNCaP prostate tumor model.
Guns, ES; Hudson, JB; Xie, X, 2001
)
2.01
"Hypericin has been found to exhibit a variety of photodynamic effects. "( Resonance Raman and surface-enhanced resonance Raman spectroscopy of hypericin.
Cotton, TM; Kolaczkowski, SV; Raser, LN, 1992
)
1.96

Actions

Hypericin was found to inhibit PIC assays, while the other compounds tested were inactive. Hypericin displays absorption within the ultraviolet (UV) A1 spectrum and there may therefore be a potential for phototoxicity if taken during high-dose UVA1 therapy.

ExcerptReferenceRelevance
"Hypericin is known to generate a high yield of singlet oxygen and other reactive oxygen species that are associated with photo-oxidative cellular damage."( Hypericin lights up the way for the potential treatment of nasopharyngeal cancer by photodynamic therapy.
Bay, BH; Du, HY; Olivo, M, 2006
)
2.5
"Hypericin did not inhibit AD-induced apoptosis and slightly enhanced CL-induced apoptosis."( Effects of polyphenolic anthrone derivatives, resistomycin and hypercin, on apoptosis in human megakaryoblastic leukemia CMK-7 cell line.
Oka, S; Seo, S; Shiono, N; Shiono, Y; Yamazaki, Y,
)
0.85
"Hypericin displays absorption within the ultraviolet (UV) A1 spectrum and there may therefore be a potential for phototoxicity if taken during high-dose UVA1 therapy."( Can St John's wort (hypericin) ingestion enhance the erythemal response during high-dose ultraviolet A1 therapy?
Beattie, PE; Dawe, RS; Ferguson, J; Ibbotson, SH; Traynor, NJ; Woods, JA, 2005
)
1.37
"Hypericin was found to inhibit PIC assays, while the other compounds tested were inactive."( Human immunodeficiency virus type 1 cDNA integration: new aromatic hydroxylated inhibitors and studies of the inhibition mechanism.
Bushman, F; Farnet, CM; Hansen, M; Lipford, JR; Robinson, WE; Siegel, J; Wang, B; Zalkow, L, 1998
)
1.02
"Hypericin displays antiproliferative and cytotoxic effects on tumor cells. "( Photodynamic treatment of basal cell carcinoma and squamous cell carcinoma with hypericin.
Alecu, M; Coman, G; de Witte, P; Hãlãlãu, F; Merlevede, W; Ursaciuc, C; Waelkens, E,
)
1.8
"Hypericin was found to inhibit autophosphorylation of the erbB-2 protein and downstream kinases such as MEK and ERK1/2."( Inhibition of c-erbB-2 expression an activity in human ovarian carcinoma cells by hypericin.
Gee, SW; Hwang, MS; Joo, JH; Kang, HI; Kim, OH; Kim, S; Lee, KK; Yum, YN,
)
1.08
"Hypericin did not inhibit the binding of recombinant gp120 to CD4+ cells, nor did hypericin inhibit syncytium formation."( Inactivation of the human immunodeficiency virus by hypericin: evidence for photochemical alterations of p24 and a block in uncoating.
Carter, C; Degar, S; Ehrlich, LS; Lavie, D; Lavie, G; Levin, B; Mazur, Y; Meruelo, D; Pascual, D; Prince, AM, 1992
)
1.26

Treatment

Hypericin treatment combined with illumination led to a 94-97% decrease in metabolic activity and caused apoptosis in nearly 100% of RCC cells. Hypericin-treatment did not inhibit retroviral production or the proteolytic cleavage of the gag-encoded precursor proteins.

ExcerptReferenceRelevance
"Hypericin treatment (6.25-50 microM) inhibited NF-kappaB, caused accumulation of phosphorylated IkappaBalpha, decreased p50 protein levels and induced cleavage of p65 protein in U373 cells."( Hypericin-an inhibitor of proteasome function.
Fiebich, B; Pajonk, F; Scholber, J, 2005
)
2.49
"Hypericin treatment combined with illumination led to a 94-97% decrease in metabolic activity and caused apoptosis in nearly 100% of RCC cells."( Photosensitizing and radiosensitizing effects of hypericin on human renal carcinoma cells in vitro.
Busse, AC; Grabbe, E; Hermann, R; Müller, GA; Rave-Fränk, M; Wessels, JT; Zänker, S,
)
1.11
"Hypericin-treatment did not inhibit retroviral production or the proteolytic cleavage of the gag-encoded precursor proteins."( Photodynamic inactivation of radiation leukemia virus produced from hypericin-treated cells.
Degar, S; Lavie, G; Meruelo, D, 1993
)
1.24
"When hypericin treated cells were not exposed to light growth inhibition was insignificant."( Light-induced photoactivation of hypericin inhibits cellular growth in pituitary adenoma cell line AtT20/D16v-F2 (hypericin inhibits cellular growth of AtT20/D16v-F2).
Cerman, J; Mareková, M; Vávrová, J; Vokurková, D, 2001
)
1.05
"Hypericin-treated recombinant HIV p24 exhibited similar altered mobility."( Inactivation of the human immunodeficiency virus by hypericin: evidence for photochemical alterations of p24 and a block in uncoating.
Carter, C; Degar, S; Ehrlich, LS; Lavie, D; Lavie, G; Levin, B; Mazur, Y; Meruelo, D; Pascual, D; Prince, AM, 1992
)
1.26
"Pretreatment with hypericin (5 μM and 15 μM) significantly suppresses oligomeric Aβ42 (oAβ42)-induced expression of interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor α (TNF α) and inducible nitric oxide synthase (iNOS) and production of NO in microglia without cytotoxicity."( Hypericin inhibits oligomeric amyloid β42-induced inflammation response in microglia and ameliorates cognitive deficits in an amyloid β injection mouse model of Alzheimer's disease by suppressing MKL1.
Li, P; Qian, F; Wang, Y; Xu, X; Zhang, M, 2016
)
2.2
"Treatment with hypericin led to a significant down-regulation (13%) of beta-AR's in the frontal cortex after 8-weeks, but not after 2 weeks, while hyperforin (used as trimethoxybenzoate, TMB), and hyperoside were ineffective in both treatment paradigms."( Extracts of St. John's wort and various constituents affect beta-adrenergic binding in rat frontal cortex.
Butterweck, V; Simbrey, K; Winterhoff, H, 2004
)
0.66
"When treated with hypericin, the cell ratio reducible of nitroblue tetrazolium was significantly increased and the cell size was enlarged by flow cytometry analysis."( Hypericin induces both differentiation and apoptosis in human promyelocytic leukemia HL-60 cells.
Chang, SG; Jung, JC; Kim, JI; Lee, KT; Miyamoto, K; Park, HJ; Park, JH; Rho, YS, 1999
)
2.07

Toxicity

ExcerptReferenceRelevance
" A low concentration of hyp (5 x 10(-9) M) was highly toxic to MRC5 cells, producing 15% survival for an irradiation period of 40 min."( Photodynamically induced cytotoxicity of hypericin dye on human fibroblast cell line MRC5.
Favier, A; Hadjur, C; Jardon, P; Parat, MO; Richard, MJ, 1995
)
0.56
" No other serious adverse events associated with hypericin use occurred."( Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection.
Cabana, BE; Feinman, L; Jacobson, JM; Koslowski, V; Lee, D; Liebes, L; Ostrow, N; Prince, AM; Spritzler, J; Tobia, A, 2001
)
0.82
" John's wort have recorded an incidence of adverse events (AE) among those treated of between 1 and 3%."( Incidence and clinical relevance of the interactions and side effects of Hypericum preparations.
Schulz, V, 2001
)
0.31
" Adverse reactions to Hypericum extract in the clinical treatment of depression include skin reddening and itching, dizziness, constipation, fatigue, anxiety, and tiredness."( Final report on the safety assessment of Hypericum perforatum extract and Hypericum perforatum oil.
, 2001
)
0.31
" This would result in toxic melanin precursors (of an indolic and phenolic nature) leaking into the cytoplasm which in turn leads to cell death."( Hypericin phototoxicity induces different modes of cell death in melanoma and human skin cells.
Davids, LM; Kacerovská, D; Kidson, SH; Kleemann, B; Pizinger, K, 2008
)
1.79
" A marked decrease in the glutathione level of a majority of cells was observed after more toxic combination treatment."( Potentiation of hypericin-mediated photodynamic therapy cytotoxicity by MK-886: focus on ABC transporters, GDF-15 and redox status.
Fedoročko, P; Jendželovská, Z; Jendželovský, R; Kovaľ, J; Kuchárová, B; Mikeš, J; Mikešová, L; Vargová, J, 2015
)
0.76
"Given that mycosis fungoides-cutaneous T-cell lymphoma (MF/CTCL) is chronic, there is a need for additional therapies with minimal short- and long-term adverse effects."( Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.
Akilov, O; Appel, J; Bhatia, N; Boh, E; Bohjanen, K; Carter, J; Dawes, K; DeSimone, JA; Donini, O; Duvic, M; Elston, D; Geskin, L; Girardi, M; Guitart, J; Haulenbeek, A; Huen, A; Kim, EJ; Kim, YH; Korman, NJ; Kuzel, TM; Lain, E; Lee, ST; Mangold, AR; Musiek, A; Nikbakht, N; Olsen, E; Pacheco, T; Pariser, D; Piette, W; Poligone, B; Pullion, C; Querfeld, C; Rook, AH; Rumage, A; Schaber, CJ; Seminario-Vidal, L; Shinohara, M; Straube, R; Wong, HK; Wood, GS; Zeitouni, N; Zwerner, JP, 2022
)
1.01
" Adverse events (AEs) were assessed at each treatment visit, after each cycle, and then monthly for 6 months."( Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.
Akilov, O; Appel, J; Bhatia, N; Boh, E; Bohjanen, K; Carter, J; Dawes, K; DeSimone, JA; Donini, O; Duvic, M; Elston, D; Geskin, L; Girardi, M; Guitart, J; Haulenbeek, A; Huen, A; Kim, EJ; Kim, YH; Korman, NJ; Kuzel, TM; Lain, E; Lee, ST; Mangold, AR; Musiek, A; Nikbakht, N; Olsen, E; Pacheco, T; Pariser, D; Piette, W; Poligone, B; Pullion, C; Querfeld, C; Rook, AH; Rumage, A; Schaber, CJ; Seminario-Vidal, L; Shinohara, M; Straube, R; Wong, HK; Wood, GS; Zeitouni, N; Zwerner, JP, 2022
)
1.01

Pharmacokinetics

The study was designed to find out whether the improved water solubility in the presence of procyanidin B2 or hyperoside is correlated to increased plasma levels of hypericin.

ExcerptReferenceRelevance
" The median elimination half-life times of hypericin were 24."( Pharmacokinetics of hypericin and pseudohypericin after oral intake of the hypericum perforatum extract LI 160 in healthy volunteers.
Brockmöller, J; Kerb, R; Ploch, M; Roots, I; Staffeldt, B, 1994
)
0.87
" The Cmax and the area under the curve values for the lowest dose were disproportionally lower than those for the higher doses."( Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin.
Brockmöller, J; Kerb, R; Ploch, M; Roots, I; Staffeldt, B, 1996
)
0.55
"A double-blind, randomized, placebo-controlled parallel-group trial (phase I) was performed to evaluate the central pharmacodynamic effects of two hypericum extracts with different contents of hyperforin (0."( Pharmacodynamic effects of two different hypericum extracts in healthy volunteers measured by quantitative EEG.
Dimpfel, W; Sauer, S; Schellenberg, R, 1998
)
0.3
" The pharmacokinetic data revealed a long elimination half-life (mean values of 36."( Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection.
Cabana, BE; Feinman, L; Jacobson, JM; Koslowski, V; Lee, D; Liebes, L; Ostrow, N; Prince, AM; Spritzler, J; Tobia, A, 2001
)
0.56
" The present pharmacokinetic study was designed to find out whether the improved water solubility in the presence of procyanidin B2 or hyperoside is correlated to increased plasma levels of hypericin."( Plasma levels of hypericin in presence of procyanidin B2 and hyperoside: a pharmacokinetic study in rats.
Butterweck, V; Liefländer-Wulf, U; Nahrstedt, A; Winterhoff, H, 2003
)
0.85
" Therefore, the objective of the two open phase I clinical trials was to obtain pharmacokinetic data of these constituents from a hypericum extract containing tablet: hypericin, pseudohypericin, hyperforin, the flavonoid aglycone quercetin, and its methylated form isorhamnetin."( Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers.
Bässler, D; Schulz, HU; Schürer, M; Weiser, D, 2005
)
0.79
" In contrast to the amount of documentation concerning clinical efficacy, oral bioavailability and pharmacokinetic data about the active components are rather scarce."( Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients.
Schubert-Zsilavecz, M; Wurglics, M, 2006
)
0.33
" An open-label, 2-period, nonrandomized, phase-I, pharmacokinetic interaction design was used."( Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial.
Calvo, A; Martínez, I; Portolés, A; Resplandy, G; Terleira, A, 2006
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Their biodistribution and pharmacokinetic properties were determined in rat models of induced necrosis."( Effects of skeleton structure on necrosis targeting and clearance properties of radioiodinated dianthrones.
Feng, Y; Gao, M; Huang, D; Jiang, C; Ni, Y; Shao, H; Sun, Z; Wang, X; Yang, S; Yin, Z; Zhang, D; Zhang, J, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
" However, the tumors administered with a initial dose of CX at 24-h post-PDT had no tumor control."( Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma.
Olivo, M; Soo, KC; Yee, KK, 2005
)
0.63
" Avastin (bevacizumab), a vascular endothelial growth factor (VEGF) specific monoclonal antibody in combination with chemotherapy is offering hope to patients with metastatic colorectal cancer."( Hypericin-mediated photodynamic therapy in combination with Avastin (bevacizumab) improves tumor response by downregulating angiogenic proteins.
Bhuvaneswari, R; Chee, SK; Olivo, M; Yuen, GY, 2007
)
1.78
" We use confocal endomicroscopy to study the antiangiogenic effects of PDT in combination with bevacizumab."( Evaluation of hypericin-mediated photodynamic therapy in combination with angiogenesis inhibitor bevacizumab using in vivo fluorescence confocal endomicroscopy.
Bhuvaneswari, R; Gan, YY; Olivo, M; Soo, K; Soo, KC; Thong, PS,
)
0.49
" A promising approach could be photodynamic inactivation (PDI) which uses light in combination with a photosensitizer to induce a phototoxic reaction."( Phototoxic effect of hypericin alone and in combination with acetylcysteine on Staphylococcus aureus biofilms.
Djavid, GE; Karami, S; Kashef, N, 2015
)
0.74

Bioavailability

Hypericin incorporated in emulsifying ointment with solketal is well absorbed by the skin of the mice. Co-effectors in the extract improve the bioavailability of active constituents such as hypericin (1) (pharmacokinetic synergy)

ExcerptReferenceRelevance
" We conclude that hypericin is absorbed through the intestinal epithelium by passive transcellular diffusion and that increasing its solubility by cyclodextrin appears as a promising approach to increase its oral bioavailability for pharmaceutical formulations."( Binding, uptake, and transport of hypericin by Caco-2 cell monolayers.
Hoelzl, J; Lehr, CM; Sattler, S; Schaefer, U; Schneider, W, 1997
)
0.91
" administered hypericin (40 mg/kg), indicating that hypericin incorporated in emulsifying ointment with solketal is well absorbed by the skin of the mice."( Skin photosensitization with topical hypericin in hairless mice.
de Witte, PA; Kamuhabwa, AR; Roelandts, R,
)
0.76
" Chronic use of Saint John's wort (SJW) has been shown to lower the bioavailability for a variety of co-administered drugs including indinavir, cyclosporin, and digoxin."( Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure.
Greenblatt, DJ; Perloff, MD; Shader, RI; Störmer, E; von Moltke, LL, 2001
)
0.31
" Both compounds increased the oral bioavailability of hypericin by ca."( Plasma levels of hypericin in presence of procyanidin B2 and hyperoside: a pharmacokinetic study in rats.
Butterweck, V; Liefländer-Wulf, U; Nahrstedt, A; Winterhoff, H, 2003
)
0.91
"The objective of these two open phase I clinical trials was the investigation of the bioavailability of five constituents from a hypericum extract containing tablet, which are discussed as the components contributing to the antidepressant action."( Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet.
Bässler, D; Schulz, HU; Schürer, M; Weiser, D, 2005
)
0.6
" In contrast to the amount of documentation concerning clinical efficacy, oral bioavailability and pharmacokinetic data about the active components are rather scarce."( Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients.
Schubert-Zsilavecz, M; Wurglics, M, 2006
)
0.33
" In a separate experiment when mice were fed purified hypericin, the active component of St John's wort, a significant increase in bioavailability (53%) of procainamide was observed compared with the control group."( Drug-herb interaction: effect of St John's wort on bioavailability and metabolism of procainamide in mice.
Actor, JK; Dasgupta, A; Hovanetz, M; Olsen, M; Wells, A, 2007
)
0.59
"St John's wort has an acute effect to increase bioavailability of procainamide but has no effect on its metabolism."( Drug-herb interaction: effect of St John's wort on bioavailability and metabolism of procainamide in mice.
Actor, JK; Dasgupta, A; Hovanetz, M; Olsen, M; Wells, A, 2007
)
0.34
" Co-effectors in the extract improve the bioavailability of active constituents such as hypericin (1) (pharmacokinetic synergy)."( Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
Butterweck, V; Nahrstedt, A, 2010
)
0.58
" Nevertheless, the highly lipophilic nature and poor bioavailability prevent its application in daily clinical practice thus leading to a limited therapeutic value of hypericin."( Hypericin inclusion complexes encapsulated in liposomes for antimicrobial photodynamic therapy.
Bakowsky, U; Brüßler, J; Duse, L; Jedelska, J; Pinnapireddy, SR; Plenagl, N; Seitz, BS, 2019
)
2.15
" Supramolecular complexation of photosensitizers into cyclodextrins (CD) is promising to improve their poor solubility, compromising their bioavailability and upcoming applications in PDT."( Improved Hypericin solubility via β-cyclodextrin complexation: Photochemical and theoretical study for PDT applications.
Gusmão, LA; Machado, AEH; Perussi, JR, 2022
)
1.14

Dosage Studied

The objective of this study was to improve in vivo tumor growth control of nasopharyngeal carcinoma (NPC) Using a combination of Hypericin-PDT and COX-2 inhibitor, Celebrex (CX), maximum total hypericin plasma concentrations were observed about 4 h after dosage and were 0, 0.33% fractionated dose.

ExcerptRelevanceReference
" Viremia induced by LP-BM5 murine immunodeficiency virus is markedly suppressed after infrequent dosage of either substance."( Studies of the mechanisms of action of the antiretroviral agents hypericin and pseudohypericin.
Gallo, G; Lavie, D; Lavie, G; Levin, B; Mazur, Y; Meruelo, D; Valentine, F; Weiner, D, 1989
)
0.51
" During long-term dosing (3 x 300 mg/day), a steady-state was reached after 4 days."( Pharmacokinetics of hypericin and pseudohypericin after oral intake of the hypericum perforatum extract LI 160 in healthy volunteers.
Brockmöller, J; Kerb, R; Ploch, M; Roots, I; Staffeldt, B, 1994
)
0.61
" Also, individual products have different hypericin and hyperforin levels, and are therefore not switchable--even when products are manufactured under similar extraction and processing conditions, have the same raw material:extract ratios (on a dry basis) and contain the same amount of extract per unit dosage form."( Batch-to-batch reproducibility of St. John's wort preparations.
Baumeister, A; Dressman, J; Kaunzinger, A; Schubert-Zsilovecz, M; Westerhoff, K; Wilke, A; Wurglics, M, 2001
)
0.57
" In the FST all three extracts decreased immobility time in a dosage of 500 mg/kg after acute as well as after repeated treatment."( Step by step removal of hyperforin and hypericin: activity profile of different Hypericum preparations in behavioral models.
Butterweck, V; Christoffel, V; Nahrstedt, A; Petereit, F; Spengler, B; Winterhoff, H, 2003
)
0.59
" Concentration/time curves were determined for hypericin, pseudohypericin, hyperforin, the flavonoid aglycone quercetin, and its methylated form isorhamnetin for 48 h after single dosing and for 24 h on day 14 at the end of 2 weeks of continuous daily dosing."( Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet.
Bässler, D; Schulz, HU; Schürer, M; Weiser, D, 2005
)
0.85
" The objective of this study was to improve in vivo tumor growth control of nasopharyngeal carcinoma (NPC), treated at a subcurative dosage by using a combination of Hypericin-PDT and COX-2 inhibitor, Celebrex (CX)."( Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma.
Olivo, M; Soo, KC; Yee, KK, 2005
)
0.82
" Concentration/time curves were determined for the five constituents, for 48 h after single dosing and for 24 h on day 14 at the end of 2 weeks of continuous daily dosing."( Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers.
Bässler, D; Schulz, HU; Schürer, M; Weiser, D, 2005
)
0.59
" Despite these differences, the maximum slope of the dose-response curve was not increased after SJW ingestion."( Can St John's wort (hypericin) ingestion enhance the erythemal response during high-dose ultraviolet A1 therapy?
Beattie, PE; Dawe, RS; Ferguson, J; Ibbotson, SH; Traynor, NJ; Woods, JA, 2005
)
0.65
" All groups of PDT-treated animals with single and fractionated hypericin dosing presented primary vascular reactions including vascular dilatation, congestion, thrombosis and oedema."( Histomorphological changes in murine fibrosarcoma after hypericin-based photodynamic therapy.
Bobrov, N; Brezáni, P; Cavarga, I; Fedorocko, P; Longauer, F; Mirossay, L; Miskovský, P; Rybárová, S; Stubna, J, 2007
)
0.82
"25 μM hypericin as a photosensitiser activated via a dosage of 1 J/cm(2) yellow laser light produces an effective in vitro outcome to be considered as an important contribution towards optimising PDRT."( Laser light activation of a second-generation photosensitiser and its use as a potential photomodulatory agent in skin rejuvenation.
Davids, LM; Karsten, A; Van Kets, V, 2013
)
0.87
" One day after injection, rats were euthanized with their hearts excised for qualitative and quantitative studies by means of microscopic fluorescence examination to decide the dosage of hypericin."( Hypericin as a marker for determination of myocardial viability in a rat model of myocardial infarction.
Gao, M; Jiang, C; Jiang, X; Li, Y; Ni, Y; Sun, Z; Wang, J; Wang, X; Yao, N; Zhang, J; Zhang, X,
)
1.76
"To determine the optimum dosage and instillation time for water-soluble polyvinylpyrrolidone (PVP)-hypericin for photodynamic diagnosis of bladder cancer and to monitor its use in regard to patient safety."( A phase IIA dose-finding study of PVP-hypericin fluorescence cystoscopy for detection of nonmuscle-invasive bladder cancer.
Abrahamsberg, C; Gschwend, JE; Horn, T; Russ, D; Straub, M, 2015
)
0.9
" Different combinations of PVP-hypericin dosage (225 μg and 75 μg and instillation time (120, 60, 30, 15 min) were used to evaluate the optimal conditions."( A phase IIA dose-finding study of PVP-hypericin fluorescence cystoscopy for detection of nonmuscle-invasive bladder cancer.
Abrahamsberg, C; Gschwend, JE; Horn, T; Russ, D; Straub, M, 2015
)
0.97
"The optimum combination of dosage of PVP-hypericin and its instillation time was established and will be used to determine sensitivity and specificity of PVP-hypericin cystoscopy in a larger multicenter phase IIB study."( A phase IIA dose-finding study of PVP-hypericin fluorescence cystoscopy for detection of nonmuscle-invasive bladder cancer.
Abrahamsberg, C; Gschwend, JE; Horn, T; Russ, D; Straub, M, 2015
)
0.95
" The results have shown that photoactivated HYP can only induce primary DNA damages (single-strand DNA breaks), acting in a dose-response manner."( Photoactivated hypericin is not genotoxic.
Bodnárová, K; Chalupa, I; Feruszová, J; Gálová, E; Imreová, P; Kyzek, S; Miadoková, E; Ševčovičová, A, 2016
)
0.79
" High dosage of HY-PDT induced autophagic cell death; while low dose of HY-PDT predominantly triggered protective autophagy and promoted cell proliferation."( Endoplasmic reticulum-targeting photosensitizer Hypericin confers chemo-sensitization towards oxaliplatin through inducing pro-death autophagy.
Du, W; Liang, X; Lin, S; Liu, J; Qi, Y; Qiu, C; Shi, H; Shi, W; Yang, L, 2017
)
0.71
" Order of the sessions and dosage conditions were randomized between subjects."( The acute effect of Hypericum perforatum on short-term memory in healthy adults.
Ashby, NJS; Bar-Shaked, M; Ben-Eliezer, D; Yechiam, E, 2019
)
0.51
" Nevertheless, both formulations yielded severe photocytotoxicity in SK-OV-3 cells in a therapeutic dosage range."( Photodynamic therapy - hypericin tetraether liposome conjugates and their antitumor and antiangiogenic activity.
Bakowsky, U; Brüßler, J; Duse, L; Goergen, N; Jedelska, J; Pinnapireddy, SR; Plenagl, N; Seitz, BS, 2019
)
0.82
" HYP-LCPS induced a significant reduction in the number of CFU/ml in the mice; thus this formulation indicated it is as effective as a commercial dosage form."( In vivo study of hypericin-loaded poloxamer-based mucoadhesive in situ gelling liquid crystalline precursor system in a mice model of vulvovaginal candidiasis.
Araújo, VHS; Bauab, TM; Calixto, GMF; Chorilli, M; de Araújo, PR; Oshiro-Junior, JA; Rodero, CF; Sato, MR, 2021
)
0.96
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (1)

PathwayProteinsCompounds
hypericin biosynthesis17

Protein Targets (35)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency4.08710.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency28.18380.004023.8416100.0000AID485290
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency10.84660.125919.1169125.8920AID2549; AID2708
Chain A, Ferritin light chainEquus caballus (horse)Potency28.18385.623417.292931.6228AID485281
Chain A, CruzipainTrypanosoma cruziPotency28.18380.002014.677939.8107AID1476
phosphopantetheinyl transferaseBacillus subtilisPotency53.17640.141337.9142100.0000AID1490
TDP1 proteinHomo sapiens (human)Potency12.27980.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency21.46110.180013.557439.8107AID1460; AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency22.38720.011212.4002100.0000AID1030
luciferasePhoturis pensylvanica (Pennsylania firefly)Potency10.00000.891310.432820.5750AID1379
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency8.91250.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency28.18380.016525.307841.3999AID602332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency19.95260.540617.639296.1227AID2528
polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)Potency14.12541.000012.232631.6228AID1452
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency8.91250.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency8.91250.354828.065989.1251AID504847
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency7.56780.010039.53711,122.0200AID1469; AID1479
DNA polymerase kappa isoform 1Homo sapiens (human)Potency8.97160.031622.3146100.0000AID588579
survival motor neuron protein isoform dHomo sapiens (human)Potency17.78280.125912.234435.4813AID1458
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency17.78280.251215.843239.8107AID504327
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency2.51190.316212.765731.6228AID881
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency2.51190.00638.235039.8107AID881
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency11.29471.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thioredoxin reductase 1, cytoplasmicRattus norvegicus (Norway rat)IC50 (µMol)178.06250.27201.82606.0000AID551520
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)8.70000.00011.753610.0000AID478702
Dopamine beta-hydroxylaseHomo sapiens (human)IC50 (µMol)21.00001.20232.07793.0000AID1718567
Corticotropin-releasing factor receptor 1Homo sapiens (human)IC50 (µMol)0.30000.00070.06490.3400AID478681; AID478682
D(3) dopamine receptorHomo sapiens (human)Ki0.03450.00000.602010.0000AID478680
Cystathionine beta-synthaseHomo sapiens (human)IC50 (µMol)3.10001.00005.15718.9000AID1506494
Alpha-synucleinHomo sapiens (human)IC50 (µMol)7.50000.19003.82049.8000AID1695729
Glutathione reductaseSaccharomyces cerevisiae S288CIC50 (µMol)3.67003.67003.67003.6700AID551525
Integrase Human immunodeficiency virus 1IC50 (µMol)10.00000.00051.544310.0000AID91425
5-lipoxygenase Bos taurus (cattle)IC50 (µMol)30.00000.18001.75824.0000AID160507
Cysteine protease ATG4BHomo sapiens (human)IC50 (µMol)32.95000.63003.06558.9000AID1330871; AID1915514
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (220)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
blood vessel remodelingDopamine beta-hydroxylaseHomo sapiens (human)
response to amphetamineDopamine beta-hydroxylaseHomo sapiens (human)
leukocyte mediated immunityDopamine beta-hydroxylaseHomo sapiens (human)
chemical synaptic transmissionDopamine beta-hydroxylaseHomo sapiens (human)
memoryDopamine beta-hydroxylaseHomo sapiens (human)
locomotory behaviorDopamine beta-hydroxylaseHomo sapiens (human)
visual learningDopamine beta-hydroxylaseHomo sapiens (human)
homoiothermyDopamine beta-hydroxylaseHomo sapiens (human)
vasoconstrictionDopamine beta-hydroxylaseHomo sapiens (human)
dopamine catabolic processDopamine beta-hydroxylaseHomo sapiens (human)
norepinephrine biosynthetic processDopamine beta-hydroxylaseHomo sapiens (human)
glucose homeostasisDopamine beta-hydroxylaseHomo sapiens (human)
fear responseDopamine beta-hydroxylaseHomo sapiens (human)
maternal behaviorDopamine beta-hydroxylaseHomo sapiens (human)
positive regulation of vasoconstrictionDopamine beta-hydroxylaseHomo sapiens (human)
behavioral response to ethanolDopamine beta-hydroxylaseHomo sapiens (human)
response to painDopamine beta-hydroxylaseHomo sapiens (human)
leukocyte migrationDopamine beta-hydroxylaseHomo sapiens (human)
positive regulation of cold-induced thermogenesisDopamine beta-hydroxylaseHomo sapiens (human)
regulation of vascular associated smooth muscle cell proliferationDopamine beta-hydroxylaseHomo sapiens (human)
regulation of vascular endothelial cell proliferationDopamine beta-hydroxylaseHomo sapiens (human)
regulation of extrinsic apoptotic signaling pathwayDopamine beta-hydroxylaseHomo sapiens (human)
octopamine biosynthetic processDopamine beta-hydroxylaseHomo sapiens (human)
immune responseCorticotropin-releasing factor receptor 1Homo sapiens (human)
cell surface receptor signaling pathwayCorticotropin-releasing factor receptor 1Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCorticotropin-releasing factor receptor 1Homo sapiens (human)
activation of adenylate cyclase activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
female pregnancyCorticotropin-releasing factor receptor 1Homo sapiens (human)
parturitionCorticotropin-releasing factor receptor 1Homo sapiens (human)
regulation of adenylate cyclase activity involved in G protein-coupled receptor signaling pathwayCorticotropin-releasing factor receptor 1Homo sapiens (human)
adrenal gland developmentCorticotropin-releasing factor receptor 1Homo sapiens (human)
exploration behaviorCorticotropin-releasing factor receptor 1Homo sapiens (human)
fear responseCorticotropin-releasing factor receptor 1Homo sapiens (human)
behavioral response to ethanolCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotropin secretionCorticotropin-releasing factor receptor 1Homo sapiens (human)
general adaptation syndrome, behavioral processCorticotropin-releasing factor receptor 1Homo sapiens (human)
cellular response to corticotropin-releasing hormone stimulusCorticotropin-releasing factor receptor 1Homo sapiens (human)
negative regulation of voltage-gated calcium channel activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
regulation of corticosterone secretionCorticotropin-releasing factor receptor 1Homo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
endochondral ossificationCystathionine beta-synthaseHomo sapiens (human)
blood vessel remodelingCystathionine beta-synthaseHomo sapiens (human)
L-serine metabolic processCystathionine beta-synthaseHomo sapiens (human)
L-serine catabolic processCystathionine beta-synthaseHomo sapiens (human)
superoxide metabolic processCystathionine beta-synthaseHomo sapiens (human)
regulation of nitric oxide mediated signal transductionCystathionine beta-synthaseHomo sapiens (human)
cysteine biosynthetic process via cystathionineCystathionine beta-synthaseHomo sapiens (human)
cysteine biosynthetic processCystathionine beta-synthaseHomo sapiens (human)
transsulfurationCystathionine beta-synthaseHomo sapiens (human)
L-cysteine catabolic processCystathionine beta-synthaseHomo sapiens (human)
cerebellum morphogenesisCystathionine beta-synthaseHomo sapiens (human)
DNA protectionCystathionine beta-synthaseHomo sapiens (human)
negative regulation of apoptotic processCystathionine beta-synthaseHomo sapiens (human)
homocysteine catabolic processCystathionine beta-synthaseHomo sapiens (human)
homocysteine metabolic processCystathionine beta-synthaseHomo sapiens (human)
response to folic acidCystathionine beta-synthaseHomo sapiens (human)
maternal process involved in female pregnancyCystathionine beta-synthaseHomo sapiens (human)
cartilage development involved in endochondral bone morphogenesisCystathionine beta-synthaseHomo sapiens (human)
hydrogen sulfide biosynthetic processCystathionine beta-synthaseHomo sapiens (human)
cellular response to hypoxiaCystathionine beta-synthaseHomo sapiens (human)
blood vessel diameter maintenanceCystathionine beta-synthaseHomo sapiens (human)
cysteine biosynthetic process from serineCystathionine beta-synthaseHomo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
protein delipidationCysteine protease ATG4BHomo sapiens (human)
autophagosome assemblyCysteine protease ATG4BHomo sapiens (human)
mitophagyCysteine protease ATG4BHomo sapiens (human)
proteolysisCysteine protease ATG4BHomo sapiens (human)
autophagyCysteine protease ATG4BHomo sapiens (human)
protein transportCysteine protease ATG4BHomo sapiens (human)
macroautophagyCysteine protease ATG4BHomo sapiens (human)
microautophagyCysteine protease ATG4BHomo sapiens (human)
otolith mineralization completed early in developmentCysteine protease ATG4BHomo sapiens (human)
protein localization to phagophore assembly siteCysteine protease ATG4BHomo sapiens (human)
protein delipidationCysteine protease ATG4BHomo sapiens (human)
protein processingCysteine protease ATG4BHomo sapiens (human)
piecemeal microautophagy of the nucleusCysteine protease ATG4BHomo sapiens (human)
aggrephagyCysteine protease ATG4BHomo sapiens (human)
C-terminal protein lipidationCysteine protease ATG4BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (75)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
catalytic activityDopamine beta-hydroxylaseHomo sapiens (human)
dopamine beta-monooxygenase activityDopamine beta-hydroxylaseHomo sapiens (human)
copper ion bindingDopamine beta-hydroxylaseHomo sapiens (human)
protein bindingDopamine beta-hydroxylaseHomo sapiens (human)
L-ascorbic acid bindingDopamine beta-hydroxylaseHomo sapiens (human)
protein bindingCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotrophin-releasing factor receptor activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
G protein-coupled peptide receptor activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotropin-releasing hormone bindingCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotropin-releasing hormone receptor activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
cystathionine beta-synthase activityCystathionine beta-synthaseHomo sapiens (human)
protein bindingCystathionine beta-synthaseHomo sapiens (human)
oxygen bindingCystathionine beta-synthaseHomo sapiens (human)
enzyme bindingCystathionine beta-synthaseHomo sapiens (human)
heme bindingCystathionine beta-synthaseHomo sapiens (human)
pyridoxal phosphate bindingCystathionine beta-synthaseHomo sapiens (human)
ubiquitin protein ligase bindingCystathionine beta-synthaseHomo sapiens (human)
identical protein bindingCystathionine beta-synthaseHomo sapiens (human)
protein homodimerization activityCystathionine beta-synthaseHomo sapiens (human)
metal ion bindingCystathionine beta-synthaseHomo sapiens (human)
nitrite reductase (NO-forming) activityCystathionine beta-synthaseHomo sapiens (human)
carbon monoxide bindingCystathionine beta-synthaseHomo sapiens (human)
nitric oxide bindingCystathionine beta-synthaseHomo sapiens (human)
modified amino acid bindingCystathionine beta-synthaseHomo sapiens (human)
S-adenosyl-L-methionine bindingCystathionine beta-synthaseHomo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
endopeptidase activityCysteine protease ATG4BHomo sapiens (human)
cysteine-type endopeptidase activityCysteine protease ATG4BHomo sapiens (human)
protein bindingCysteine protease ATG4BHomo sapiens (human)
cysteine-type peptidase activityCysteine protease ATG4BHomo sapiens (human)
protein-phosphatidylethanolamide deconjugating activityCysteine protease ATG4BHomo sapiens (human)
scaffold protein bindingCysteine protease ATG4BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (40)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
extracellular regionDopamine beta-hydroxylaseHomo sapiens (human)
extracellular spaceDopamine beta-hydroxylaseHomo sapiens (human)
cytoplasmDopamine beta-hydroxylaseHomo sapiens (human)
endoplasmic reticulumDopamine beta-hydroxylaseHomo sapiens (human)
membraneDopamine beta-hydroxylaseHomo sapiens (human)
transport vesicle membraneDopamine beta-hydroxylaseHomo sapiens (human)
secretory granule membraneDopamine beta-hydroxylaseHomo sapiens (human)
centriolar satelliteDopamine beta-hydroxylaseHomo sapiens (human)
chromaffin granule lumenDopamine beta-hydroxylaseHomo sapiens (human)
secretory granule lumenDopamine beta-hydroxylaseHomo sapiens (human)
chromaffin granule membraneDopamine beta-hydroxylaseHomo sapiens (human)
intracellular membrane-bounded organelleDopamine beta-hydroxylaseHomo sapiens (human)
synapseDopamine beta-hydroxylaseHomo sapiens (human)
extracellular spaceDopamine beta-hydroxylaseHomo sapiens (human)
secretory granule membraneDopamine beta-hydroxylaseHomo sapiens (human)
endosomeCorticotropin-releasing factor receptor 1Homo sapiens (human)
plasma membraneCorticotropin-releasing factor receptor 1Homo sapiens (human)
membraneCorticotropin-releasing factor receptor 1Homo sapiens (human)
plasma membraneCorticotropin-releasing factor receptor 1Homo sapiens (human)
neuron projectionCorticotropin-releasing factor receptor 1Homo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
nucleusCystathionine beta-synthaseHomo sapiens (human)
cytoplasmCystathionine beta-synthaseHomo sapiens (human)
cytosolCystathionine beta-synthaseHomo sapiens (human)
cytoplasmCystathionine beta-synthaseHomo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
autophagosome membraneCysteine protease ATG4BHomo sapiens (human)
mitochondrionCysteine protease ATG4BHomo sapiens (human)
endoplasmic reticulumCysteine protease ATG4BHomo sapiens (human)
cytosolCysteine protease ATG4BHomo sapiens (human)
cytoplasmic vesicleCysteine protease ATG4BHomo sapiens (human)
cytoplasmCysteine protease ATG4BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (85)

Assay IDTitleYearJournalArticle
AID478682Inhibition of recombinant CRF1 receptor expressed in CHO cells assessed as inhibition of CRF-induced cAMP formation2010Journal of natural products, May-28, Volume: 73, Issue:5
Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
AID85482Antiproliferative (inhibition of cell growth) activity against HaCaT cells (human keratinocyte line)1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID328648Antimicrobial activity against Pseudomonas aeruginosa DSM 1128 by disk diffusion method2008Journal of natural products, Feb, Volume: 71, Issue:2
An endophytic fungus from Hypericum perforatum that produces hypericin.
AID1718540Inhibition of human sGC expressed in HUVEC cells assessed as reduction in GMP level incubated for 24 hrs in presence of NPS by ELISA2020Journal of natural products, 12-24, Volume: 83, Issue:12
Soluble Guanylate Cyclase Inhibitors Discovered among Natural Compounds.
AID283687Decrease in cellular cGMP level in frog atrial myocytes at 4 uM by immunoassay2007Journal of natural products, Apr, Volume: 70, Issue:4
Hypericin activates L-type Ca2+ channels in cardiac myocytes.
AID1718567Inhibition of Dopamine beta-hydroxylase (unknown origin) incubated for 10 mins2020Journal of natural products, 12-24, Volume: 83, Issue:12
Soluble Guanylate Cyclase Inhibitors Discovered among Natural Compounds.
AID1718549Inhibition of human sGC expressed in HUVEC cells assessed as reduction in GMP level at 2 uM in presence of NPS by ELISA relative to control2020Journal of natural products, 12-24, Volume: 83, Issue:12
Soluble Guanylate Cyclase Inhibitors Discovered among Natural Compounds.
AID1718552Inhibition of human sGC expressed in HUVEC cells assessed as reduction in GMP level at 20 uM in presence of NPS/BAY-412272 by ELISA relative to control2020Journal of natural products, 12-24, Volume: 83, Issue:12
Soluble Guanylate Cyclase Inhibitors Discovered among Natural Compounds.
AID283686Inhibition of NOS2 in frog atrial myocytes2007Journal of natural products, Apr, Volume: 70, Issue:4
Hypericin activates L-type Ca2+ channels in cardiac myocytes.
AID285172Effect on Streptococcus mutans LMG 14558 assessed as inhibition of biofilm formation in modified Robbin's device at 5 ug/ml relative to BHIS control2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones.
AID328647Antimicrobial activity against Klebsiella pneumoniae ssp. ozaenae DSM 681 by disk diffusion method2008Journal of natural products, Feb, Volume: 71, Issue:2
An endophytic fungus from Hypericum perforatum that produces hypericin.
AID478684Reduction in %5HT1A receptor mRNA expression in rat hippocampus at 0.2 mg/kg, po, qd for 8 weeks2010Journal of natural products, May-28, Volume: 73, Issue:5
Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID283685Inhibition of PP2A in frog atrial myocytes by microscystin assay2007Journal of natural products, Apr, Volume: 70, Issue:4
Hypericin activates L-type Ca2+ channels in cardiac myocytes.
AID472353Cytotoxicity against human THP1 cells after 48 hrs assessed morphological changes compound exposed to light for 20 mins before treatment2009Journal of natural products, Oct, Volume: 72, Issue:10
Light-independent metabolomics of endophytic Thielavia subthermophila provides insight into microbial hypericin biosynthesis.
AID1718546Selectivity ratio of IC50 for inhibition of human sGC expressed in HUVEC cells assessed as reduction in GMP level incubated for 2 hrs to human sGC expressed in HUVEC cells assessed as reduction in GMP level incubated for 2 hrs in presence of NPS2020Journal of natural products, 12-24, Volume: 83, Issue:12
Soluble Guanylate Cyclase Inhibitors Discovered among Natural Compounds.
AID285171Activity against planktonic Streptococcus mutans LMG 145582007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones.
AID551527Inhibition of rat liver cytosolic TrxR1 at 20 uM after 2 mins by spectrophotometry2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones.
AID1718556Inhibition of bovine lung sGC assessed as reduction in GMP level incubated for 2 to 12 hrs in presence of NPS by ELISA2020Journal of natural products, 12-24, Volume: 83, Issue:12
Soluble Guanylate Cyclase Inhibitors Discovered among Natural Compounds.
AID478683Reduction in corticotropin-releasing hormone mRNA expression in rat hyphalamic paraventricular nucleus at 0.2 mg/kg, po, qd for 8 weeks2010Journal of natural products, May-28, Volume: 73, Issue:5
Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
AID1605075-LO inhibitory activity was determined by inhibition of LTB4 biosynthesis in bovine polymorphonuclear leukocytes (PMNL)1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID472354Cytotoxicity against human THP1 cells after 48 hrs assessed as morphological changes in the dark condition2009Journal of natural products, Oct, Volume: 72, Issue:10
Light-independent metabolomics of endophytic Thielavia subthermophila provides insight into microbial hypericin biosynthesis.
AID551521Inhibition of rat liver mitochondrial TrxR2 by spectrophotometry2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones.
AID328652Antimicrobial activity against Candida albicans DSM 1386 by disk diffusion method2008Journal of natural products, Feb, Volume: 71, Issue:2
An endophytic fungus from Hypericum perforatum that produces hypericin.
AID1718548Inhibition of bovine lung sGC assessed as reduction in GMP level incubated for 2 hrs in presence of BAY-412272 by ELISA2020Journal of natural products, 12-24, Volume: 83, Issue:12
Soluble Guanylate Cyclase Inhibitors Discovered among Natural Compounds.
AID328649Antimicrobial activity against Salmonella enterica ssp. enterica DSM 9898 by disk diffusion method2008Journal of natural products, Feb, Volume: 71, Issue:2
An endophytic fungus from Hypericum perforatum that produces hypericin.
AID478681Inhibition of CRF1 receptor2010Journal of natural products, May-28, Volume: 73, Issue:5
Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
AID285182Effect on membrane fluidity of DPH-labeled Streptococcus mutans LMG 14558 in BHI medium assessed as fluorescence anisotropy at 5 ug/ml relative to BHI control2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones.
AID1718547Inhibition of bovine lung sGC assessed as reduction in GMP level incubated for 2 hrs in presence of NPS/BAY-412272 by ELISA2020Journal of natural products, 12-24, Volume: 83, Issue:12
Soluble Guanylate Cyclase Inhibitors Discovered among Natural Compounds.
AID1718559Inhibition of angiogenesis in HEPC-CB1 cells assessed as decrease in pseudovessels at 10 uM after 13 hrs by fluorescence inverted microscopic analysis2020Journal of natural products, 12-24, Volume: 83, Issue:12
Soluble Guanylate Cyclase Inhibitors Discovered among Natural Compounds.
AID551525Inhibition of yeast glutathione reductase by spectrophotometry2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones.
AID478699Permeability across apical to basolateral side in human Caco-2 cells2010Journal of natural products, May-28, Volume: 73, Issue:5
Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
AID1718566Inhibition of rat small intestine GST using CDNB as substrate by spectrophotometric method2020Journal of natural products, 12-24, Volume: 83, Issue:12
Soluble Guanylate Cyclase Inhibitors Discovered among Natural Compounds.
AID328646Antimicrobial activity against Staphylococcus aureus ssp. Aureus DSM 799 by disk diffusion method2008Journal of natural products, Feb, Volume: 71, Issue:2
An endophytic fungus from Hypericum perforatum that produces hypericin.
AID1718543Inhibition of bovine lung sGC assessed as reduction in GMP level incubated for 2 hrs in presence of NPS by ELISA2020Journal of natural products, 12-24, Volume: 83, Issue:12
Soluble Guanylate Cyclase Inhibitors Discovered among Natural Compounds.
AID1506496Selectivity ratio of IC50 for N-terminal His-tagged CSE extracted from human HepG2 cells expressed in Escherichia coli BL21 (DE3) using cysteine as substrate assessed as decrease in H2S production to IC50 for full-length GST-fused human CBS using cysteine2017MedChemComm, Jan-01, Volume: 8, Issue:1
Discovery of selective cystathionine β-synthase inhibitors by high-throughput screening with a fluorescent thiol probe.
AID233179Antioxidant potential was assessed from reducing activity against 2,2,di-phenyl-1-picrylhydrazyl.1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID1506497Reversible inhibition of full-length GST-fused human CBS using cysteine/homocysteine as substrate assessed as decrease in H2S production at 100 uM preincubated for 1 hr followed by ultrafiltration for 5 times2017MedChemComm, Jan-01, Volume: 8, Issue:1
Discovery of selective cystathionine β-synthase inhibitors by high-throughput screening with a fluorescent thiol probe.
AID551520Inhibition of rat liver cytosolic TrxR1 by spectrophotometry2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones.
AID1718557Inhibition of angiogenesis in HEPC-CB1 cells assessed as decrease in total length of pseudovessels at 10 uM after 13 hrs by fluorescence inverted microscopic analysis2020Journal of natural products, 12-24, Volume: 83, Issue:12
Soluble Guanylate Cyclase Inhibitors Discovered among Natural Compounds.
AID551526Inhibition of rat liver cytosolic TrxR1 at 20 uM after 1 hr by spectrophotometry2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones.
AID85486Cytotoxic activity (2 uM) was measured by the amount of LDH (mU) release in HaCaT cells.1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID1695729Inhibition of human alpha-synuclein filament formation expressed in Escherichia coli BL21(DE3) cells incubated for 72 hrs by thioflavin S based fluorescence assay2019European journal of medicinal chemistry, Apr-01, Volume: 167Toward the discovery and development of effective modulators of α-synuclein amyloid aggregation.
AID1506494Inhibition of full-length GST-fused human CBS using cysteine/homocysteine as substrate assessed as decrease in H2S production preincubated for 3 mins in presence of homocysteine and lead nitrate followed by cysteine addition2017MedChemComm, Jan-01, Volume: 8, Issue:1
Discovery of selective cystathionine β-synthase inhibitors by high-throughput screening with a fluorescent thiol probe.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID231071Peroxidant property was expressed as ratio of uMol of malondialdehyde and mMol of deoxyribose released by 75 uM test compound1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID91425Inhibition of HIV-1 integrase, under 1 uM for the 3''-preprocessing2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Developing a dynamic pharmacophore model for HIV-1 integrase.
AID328651Antimicrobial activity against Aspergillus niger DSM 1988 by disk diffusion method2008Journal of natural products, Feb, Volume: 71, Issue:2
An endophytic fungus from Hypericum perforatum that produces hypericin.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1847095Inhibition of Hepatitis C virus NS3 helicase measured by fluorescence helicase assay2021European journal of medicinal chemistry, Nov-05, Volume: 223Recent advances of quinones as a privileged structure in drug discovery.
AID478676Antidepressant activity in rat assessed as immobility time at 0.08 mg/kg, po by forced swimming test (Rvb = 158.7 +/- 8.9 sec)2010Journal of natural products, May-28, Volume: 73, Issue:5
Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
AID1718550Selectivity ratio of inhibition of human sGC expressed in HUVEC cells assessed as reduction in GMP level at 2 uM in presence of NPS to inhibition of human sGC expressed in HUVEC cells assessed as reduction in GMP level at 2 uM in presence of NPS/BAY-412272020Journal of natural products, 12-24, Volume: 83, Issue:12
Soluble Guanylate Cyclase Inhibitors Discovered among Natural Compounds.
AID1718542Inhibition of human sGC expressed in HUVEC cells assessed as reduction in GMP level incubated for 2 hrs by ELISA2020Journal of natural products, 12-24, Volume: 83, Issue:12
Soluble Guanylate Cyclase Inhibitors Discovered among Natural Compounds.
AID19630Partition coefficient (logP)1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID478702Inhibition of CYP3A42010Journal of natural products, May-28, Volume: 73, Issue:5
Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
AID285181Decrease in membrane fluidity of Streptococcus mutans LMG 14558 using pyrene in BHI medium at 5 ug/ml relative to BHI control2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones.
AID478698Plasma concentration in po dosed rat after 270 mins2010Journal of natural products, May-28, Volume: 73, Issue:5
Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
AID551530Inhibition of rat liver mitochondrial TrxR2 at 100 uM by spectrophotometry in presence of 0.25 mM NADPH2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones.
AID551529Inhibition of rat liver cytosolic TrxR1 at 100 uM by spectrophotometry in presence of 0.25 mM NADPH2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones.
AID478678Antidepressant activity in rat assessed as immobility time at 0.5 mg/kg, po by forced swimming test (Rvb = 158.7 +/- 8.9 sec)2010Journal of natural products, May-28, Volume: 73, Issue:5
Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
AID478677Antidepressant activity in rat assessed as immobility time at 0.23 mg/kg, po by forced swimming test (Rvb = 158.7 +/- 8.9 sec)2010Journal of natural products, May-28, Volume: 73, Issue:5
Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID478680Binding affinity to dopamine D3 receptor2010Journal of natural products, May-28, Volume: 73, Issue:5
Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
AID328650Antimicrobial activity against Escherichia coli DSM 682 by disk diffusion method2008Journal of natural products, Feb, Volume: 71, Issue:2
An endophytic fungus from Hypericum perforatum that produces hypericin.
AID478700Permeability across basolateral to apical side in human Caco-2 cells2010Journal of natural products, May-28, Volume: 73, Issue:5
Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1915514Inhibition of ATG4B (unknown origin) using proLC3B as substrate by FRET-LC3 assay2021European journal of medicinal chemistry, Jan-01, Volume: 209Targeting Atg4B for cancer therapy: Chemical mediators.
AID1330871Inhibition of Atg4B (unknown origin) using YFP-LC3B-EmGFP as substrate after 40 mins by FRET-based assay2016European journal of medicinal chemistry, Nov-10, Volume: 123Inhibitor screening and enzymatic activity determination for autophagy target Atg4B using a gel electrophoresis-based assay.
AID283684Activity at L-type calcium channel in frog atrial myocytes assessed as increase in Sr2+ current2007Journal of natural products, Apr, Volume: 70, Issue:4
Hypericin activates L-type Ca2+ channels in cardiac myocytes.
AID1718558Inhibition of angiogenesis in HEPC-CB1 cells assessed as decrease in number of closed structures at 10 uM after 13 hrs by fluorescence inverted microscopic analysis2020Journal of natural products, 12-24, Volume: 83, Issue:12
Soluble Guanylate Cyclase Inhibitors Discovered among Natural Compounds.
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347157Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1808021Inhibition of porcine heart malate dehydrogenase assessed as reduction in enzyme inhibition at 3 times IC50 preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec in presence of 0.01% Triton-X100 by spectrop2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID1808022Inhibition of porcine heart malate dehydrogenase assessed as critical aggregation concentration preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec by spectrophotometric method2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID1808020Inhibition of porcine heart malate dehydrogenase preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec by spectrophotometric method2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID1808029Inhibition of SARS-COV2 main protease2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (906)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (1.43)18.7374
1990's126 (13.91)18.2507
2000's362 (39.96)29.6817
2010's306 (33.77)24.3611
2020's99 (10.93)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.67 (24.57)
Research Supply Index6.92 (2.92)
Research Growth Index5.66 (4.65)
Search Engine Demand Index99.96 (26.88)
Search Engine Supply Index3.03 (0.95)

This Compound (42.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials31 (3.16%)5.53%
Reviews62 (6.31%)6.00%
Case Studies8 (0.81%)4.05%
Observational0 (0.00%)0.25%
Other881 (89.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase 3 Study Efficacy and Tolerance: The Use of 2 Phytomedicines in Association GAMALINE® 900mg + HIPERICIN® 300mg for the Treatment of Pre-Menstrual Syndrome (PMS) and Vasomotor Symptoms [NCT01365676]Phase 3240 participants (Anticipated)Interventional2012-03-31Not yet recruiting
Pilot Study of HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL [NCT06149247]Phase 210 participants (Anticipated)Interventional2023-12-05Recruiting
Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light [NCT05872854]Phase 250 participants (Anticipated)Interventional2023-08-21Recruiting
A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected Subjects [NCT00000792]Phase 124 participants InterventionalCompleted
Phase 2 Study Evaluating SGX302 (Synthetic Hypericin) in the Treatment of Mild-to-Moderate Psoriasis [NCT05442190]Phase 242 participants (Anticipated)Interventional2022-12-14Recruiting
A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 Lymphocytes [NCT00000645]Phase 132 participants InterventionalCompleted
Phase 2a Study of Systemic PK and Serial ECG Determinations Following 8 Weeks of HyBryte Treatment [NCT05380635]Phase 29 participants (Actual)Interventional2022-05-09Completed
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma [NCT02448381]Phase 3169 participants (Actual)Interventional2015-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT02448381 (2) [back to overview]Patch Lesion Response Rates With Extended Treatment (Cycle 1 & 2 SGX301 vs Cycle 1 Placebo)
NCT02448381 (2) [back to overview]Plaque Lesion Response Rates With Extended Treatment (Cycle 1 & 2 SGX301 vs Cycle 1 Placebo)
NCT05380635 (2) [back to overview]Electrocardiograms (ECG)
NCT05380635 (2) [back to overview]Systemic Blood Levels

Patch Lesion Response Rates With Extended Treatment (Cycle 1 & 2 SGX301 vs Cycle 1 Placebo)

"The proportion of patch lesions achieving a treatment response at Week 16 in the SGX301 treatment group compared to Week 8 in the Placebo treatment group. A treatment response was defined as a ≥50% improvement in CAILS score when compared to the CAILS score at baseline for individual lesions.~The Composite Assessment of Index Lesion Disease Severity (CAILS) score was measured as previously described." (NCT02448381)
Timeframe: 16 weeks

Interventionlesions with response (Number)
SGX301 (Cycle 1 & 2 = SGX301)65
Placebo (Cycle 1)14

[back to top]

Plaque Lesion Response Rates With Extended Treatment (Cycle 1 & 2 SGX301 vs Cycle 1 Placebo)

"The proportion of plaque lesions achieving a treatment response at Week 16 in the SGX301 treatment group compared to Week 8 in the Placebo treatment group. A treatment response was defined as a ≥50% improvement in CAILS score when compared to the CAILS score at baseline for individual lesions.~The Composite Assessment of Index Lesion Disease Severity (CAILS) score was measured as previously described." (NCT02448381)
Timeframe: 16 weeks

Interventionlesions with response (Number)
SGX301 (Cycle 1 & 2 = SGX301)64
Placebo (Cycle 1)7

[back to top]

Electrocardiograms (ECG)

Assess any ECG QT interval changes (defined as any occurrences of QT interval >500 ms or changes in QT interval >60 ms) during standard HyBryte photodynamic therapy. (NCT05380635)
Timeframe: 10 weeks

InterventionParticipants (Count of Participants)
HyBryte (0.25 % Hypericin)0

[back to top]

Systemic Blood Levels

Assess the systemic blood levels of hypericin during standard HyBryte photodynamic therapy. (NCT05380635)
Timeframe: 10 weeks

Interventionug/mL (Mean)
HyBryte (0.25 % Hypericin)0.00013

[back to top]